WASHINGTON — The Department of Health and Human Services has issued a policy temporarily permitting compounding pharmacies to produce certain peptide products, expanding access to experimental wellness treatments popular among advocates of the “Make America Healthy Again” movement.
Under the guidance, HHS will exercise “enforcement discretion” — refraining from action against state-licensed pharmacies, federal facilities, or licensed physicians compounding the six peptides previously endorsed by a Food and Drug Administration advisory committee.
Also Read
- Access to Emergency Supplies Remains Out of Reach for Vulnerable Communities
- Patient‑Centric Advances in OCD Treatment and Innovation
- U.S. Biopharma Industry Splits Over Treasury’s Proposed Restrictions on Chinese Biotech Investments
- Rare Stomach Twist and Bowel Block Emerge Eight Years After Gastric Plication